Marco Investment Management LLC Sells 23 Shares of Eli Lilly and Company (NYSE:LLY)

Marco Investment Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,230 shares of the company’s stock after selling 23 shares during the period. Marco Investment Management LLC’s holdings in Eli Lilly and Company were worth $1,300,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Simon Quick Advisors LLC boosted its holdings in Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at about $363,000. Terril Brothers Inc. boosted its holdings in Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after acquiring an additional 429 shares during the last quarter. Hartline Investment Corp boosted its holdings in Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after acquiring an additional 248 shares during the last quarter. Finally, Meritage Portfolio Management boosted its holdings in Eli Lilly and Company by 23.4% in the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after acquiring an additional 1,208 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.6 %

Shares of Eli Lilly and Company stock opened at $737.86 on Monday. The business’s 50 day simple moving average is $761.79 and its 200 day simple moving average is $667.10. Eli Lilly and Company has a 52-week low of $392.26 and a 52-week high of $800.78. The firm has a market cap of $701.09 billion, a PE ratio of 127.22, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter last year, the firm earned $2.09 EPS. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Morgan Stanley raised their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.